Newlink Genetics (NLNK +4.3%) gains today after European regulators grant orphan drug status for...

|By:, SA News Editor

Newlink Genetics (NLNK +4.3%) gains today after European regulators grant orphan drug status for Algenpantucel-L, the company's off-the-shelf product candidate for treatment of pancreatic cancer. The drug is currently is in Phase III testing in the U.S.